Carfilzomib Combination Extends PFS by 8.7 Months in Phase III Myeloma Trial

Silas Inman
Published Online: August 4, 2014
Robert A. Bradway

Robert A. Bradway

The combination of carfilzomib (Kyprolis), lenalidomide (Revlimid), and low-dose dexamethasone extended progression-free survival (PFS) by 8.7 months compared with lenalidomide and dexamethasone alone for patients with relapsed multiple myeloma, according to early results from the phase III ASPIRE trial.

In the ASPIRE trial, 792 patients with multiple myeloma who had received at least 1 prior therapy were randomized to lenalidomide and low-dose dexamethasone with or without the proteasome inhibitor carfilzomib. At an interim analysis, the median PFS was 26.3 months with the addition of carfilzomib arm compared with 17.6 months in the control arm (HR=0.69; 95% CI, 0.57-0.83; P <.0001).

Enrollment in the ASPIRE trial completed in February 2012. The number of events needed for a complete analysis of overall survival was not yet reached at the interim analysis. However, a trend favoring the carfilzomib arm was observed. Safety findings were consistent with previous clinical trials.

Amgen and its subsidiary Onyx Pharmaceuticals announced these early results along with plans for a regulatory filing in 2015. A full analysis from the study is expected later this year at the 2014 ASH Annual Meeting.

“In the treatment of patients with multiple myeloma, periods of remission become shorter following each treatment regimen, underscoring the need for new options. The results of the ASPIRE study demonstrate that Kyprolis can significantly extend the time patients live without their disease progressing,” Pablo J. Cagnoni, MD, president, Onyx Pharmaceuticals, said in a press release. “The ability of novel therapies to produce deep and durable responses may, one day, transform this uniformly fatal disease to one that is chronic and manageable.”

The ASPIRE study was preceded by a phase I/II dose escalation trial that evaluated the carfilzomib combination in patients with relapsed and/or refractory multiple myeloma. In this trial, the maximum planned dose for carfilzomib was 20mg/m2 on days 1 and 2 of the first cycle followed by 27 mg/m2 for subsequent cycles. Lenalidomide and low-dose dexamethasone were delivered at standard doses. This same dosing schedule was utilized in the ASPIRE trial.

According to results from the trial that were presented at the 2013 ASCO Annual Meeting, at the maximum planned dose the overall response rate in patients treated with the carfilzomib combination was 76.9% for a median duration of 22.1 months. The median PFS was 15.4 months.

The most common grade 3/4 adverse events included neutropenia (23%), thrombocytopenia (15%), anemia (15%), hypophosphatemia (13%), fatigue (12%), hyperglycemia (8%), lymphopenia (8%), hyponatremia (6%), diarrhea (6%) and pneumonia (6%).

In the collection of clinical trials exploring the drug, adverse events were recorded from 526 patients. Cardiac death was reported in 7% of these patients, pulmonary arterial hypertension in 2%, grade 3 dyspnea was reported in 5%, and all-grade dyspnea was apparent in 34%. Some cases of hepatic failure were also noted with carfilzomib, in <1% of patients treated with the drug.

“We are excited about these clinical results and the positive prospects they suggest for patients with multiple myeloma,” Robert A. Bradway, chairman and chief executive officer of Amgen, said in a statement. “Our mission at Amgen is to serve patients by advancing medicines that address serious disease. Kyprolis is an important building block in our robust, differentiated pipeline.”

Related Articles
Andrzej Jakubowiak, MD, PhD, professor of medicine, director, Myeloma Program, University of Chicago Medicine, discusses the toxicity profile of panobinostat in combination with bortezomib and dexamethasone in relapsed or relapsed/refractory multiple myeloma as seen in the PANORAMA trial.
Treatment with single-agent carfilzomib (Kyprolis) was unable to significantly extend overall survival (OS) compared with best supportive care in heavily pretreated patients with multiple myeloma.
The FDA has expanded the bortezomib (Velcade) label to allow for retreatment in patients with multiple myeloma who previously responded to the proteasome inhibitor.
Angela Dispenzieri, MD, a professor of medicine in the division of hematology at the Mayo Clinic, discusses the results of the PANORAMA 1 trial: a randomized, double-blind, phase III study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
JTT Articles
Bromodomain Inhibitor Shows Activity in Hematologic Malignancies
Immunotherapies in CRPC: Progress Evident but Not Without Challenges
A Long-Awaited Treatment Option for Radioiodine- Refractory DTC
External Resources

AJMC
HCPLive
OncLive
PainLive
Pharmacy Times
Physicians' Education Resource
Physician's Money Digest
Internal Resources

Articles
Fellows
Publications
Targeted Communications
Resources
Connect With Us:

About Us
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright TargetedOnc 2013
Intellisphere, LLC. All Rights Reserved.